Business Wire

Independent large real-world study comparing NOACs in AF-patients

Share

The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-harm profile than both warfarin and rivaroxaban. The study analysed a database of patients enrolled in US Medicare with non-valvular atrial fibrillation (NVAF) treated with either a standard dose of a non-vitamin K antagonist oral anticoagulants (NOAC, i.e. dabigatran, rivaroxaban or apixaban) or warfarin.1

Recently, the Summary of Product Characteristics (SmPC) for dabigatran in the EU was updated with information from the results of a previous large independent Medicare study, which was published in Circulation in 2015. In the study, dabigatran was associated with reduced risk of ischaemic stroke, intracranial haemorrhage and mortality and increased risk of gastrointestinal bleeding in elderly NVAF patients compared to warfarin. The risk of major bleeding was similar across both study drugs.2

According to the 2019 independent real-world study, compared to warfarin, each NOAC investigated was associated with reduced risk of thromboembolic stroke (20-29% reduction; P=0.002 [dabigatran], P<0.001 [rivaroxaban, apixaban]), intracranial haemorrhage (35-62% reduction; P<0.001 [each NOAC]), and mortality (19-34% reduction; P<0.001 [each NOAC]).1

The most recent study also compared the individual NOACs with each other. According to the results, both dabigatran and apixaban demonstrated decreased risks of intracranial haemorrhage, major extracranial bleeding, and death, compared with rivaroxaban.1

Overall, the authors concluded that among the NOACs, apixaban and dabigatran had a more favourable benefit-harm profile than rivaroxaban.1

“This independent study from 2019 is a positive reminder of dabigatran’s demonstrated safety profile, compared to both warfarin and rivaroxaban,” said Dr Waheed Jamal, Corporate Vice President, Head of Cardiometabolic Medicine, Boehringer Ingelheim. “Also, it is quite unique that a non-interventional study based on a retrospective assessment of a specific database has been accepted by a Health Authority to be added to the product label. Both this and the new comparative data add further credibility to the body of evidence demonstrating the favourable safety and efficacy profile of Pradaxa® in its licensed indications.”

The 2019 study was carried out by independent researchers including David J. Graham, MD, MPHm, and funded by US Food and Drug Administration (FDA). The retrospective, propensity-matched study analysed data from NVAF patients (≥ 65 years old) enrolled in US Medicare between Oct. 2010 and Sept. 2015. Only those initiating on warfarin (183,318) or standard US dose of dabigatran (86,198), rivaroxaban (106,389), or apixaban (73,039) were included.

The 2015 study was also carried out by independent researchers, led by David J. Graham, MD, MPHm, and was funded through an intra-agency agreement between the Centers for Medicare & Medicaid Services and the FDA. The retrospective study analysed data from NVAF patients (≥ 65 years old) initiating dabigatran or warfarin for the treatment of nonvalvular AF, who were enrolled in US Medicare between Oct. 2010 and Dec. 2012. Dabigatran users (67,207) were propensity score matched to warfarin users in a 1:1 ratio. Patients who had received prior treatment with a study medication or rivaroxaban or apixaban were excluded from the study.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/real-world-study-comparing-noacs-af-patients

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Contact information

Media Contact
Boehringer Ingelheim
Corporate Communications
Media + PR
Meike Bausinger
55216 Ingelheim/Germany
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 201916.7.2019 20:05:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, August 1, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the confere

MSCI Schedules Investor Conference Call to Review Second Quarter 2019 Results16.7.2019 14:49:00 CESTPress release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today it will release its results for second quarter 2019 on Thursday, August 1, 2019. MSCI's senior management will review the second quarter 2019 results on Thursday, August 1, 2019 at 11:00 AM Eastern Time. To listen to the live event, visit the events and presentations section of MSCI's Investor Relations homepage, http://ir.msci.com/events.cfm, or dial 1-877-376-9931 conference ID: 7743929 within the United States. International callers dial 1-720-405-2251 conference ID: 7743929. The earnings release and related investor presentation used during the conference call will be made available on MSCI's Investor Relations homepage. An audio recording of the conference call will be available on our Investor Relations website, http://ir.msci.com/events.cfm, beginning approximately two hours after the conclusion of the live event. Through August 4, 2019,

Keio Plaza Hotel Tokyo Offers “Tea Ceremony Experience and Luxurious Accommodations for Families” Package16.7.2019 14:05:00 CESTPress release

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will begin offering a special summer accommodation package entitled “Tea Ceremony Experience and Luxurious Accommodations for Families” from July 20 to September 1, 2019. This accommodation package has been specially designed to keep families with children entertained by providing the unique cultural experience of a Japanese tea ceremony as fond memories of their summer vacation at our Hotel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005325/en/ With the accommodation package, guests with children could experience unique cultural Japanese tea ceremony to learn how to make a green tea and its history. (Photo: Business Wire) The rooms offered in this accommodation package are the very popular “Two Queen Beds Rooms” located on the “Premier Grand” club floors with use of the Club Lounge included. The rooms are

Andersen Global Enters Senegal, Expands Presence in Africa16.7.2019 13:30:00 CESTPress release

Andersen Global is proud to announce a collaboration agreement with Cabex, one of the oldest legal and tax consulting firms in Senegal. Senegal thus becomes the thirteenth African country where Andersen Global has a member or collaborating firm offering legal services. Located in Dakar, Cabex has been offering services to local and foreign clients from the public and para-public sectors on matters relating to national and international issues for nearly thirty years. “Collaborating with Andersen Global shall expand our international scope and our transborder capabilities while giving us additional opportunities to expand into new markets,” Papa Alassane Ndir, Partner & General Manager at Cabex, said. “Henceforth, we are going to collaborate with many colleagues and experts from around the world and will be in a position to provide our clients more in-depth expertise.” Cherif Diaite, Partner & Technical Manager at Cabex, indicated that, “Owing to the challenge at an international level,

Mercatus Opens UK Office; Hires Chris Webb to Lead European Operations16.7.2019 13:00:00 CESTPress release

Mercatus, a leading asset and investment management platform for alternative investors and asset managers, today announced the opening of its European Headquarters in London, UK and the addition of Chris Webb as Senior Director leading the office in London. Chris was formerly a Global Director of Strategic Business Growth at FIS, with a deep focus on, and expertise in, alternative investments. “As Alternative fund managers and investors across Europe continue to embrace technology – and data – as a competitive weapon to drive future accelerated growth, we’re putting our resources in some of the largest markets. Our London office will be a critical hub for our workings in the UK, expanding upon our other offices in Silicon Valley, New York, Austin, Rome and Pune, India,” said Haresh Patel CEO of Mercatus. “We will continue to expand our local presence across Europe and Asia as our customers have deal and asset management teams in 118 countries with $540B AUM operating within the Mercatu

LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula16.7.2019 13:00:00 CESTPress release

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received CE Mark earlier this year and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery procedures requiring femoral artery cannulation. In a clinical study, Bi-Flow was easily inserted and removed without complications and was proven to provide simultaneous systemic and distal perfusion of the limb in a safe and reproducible way.1 Leg ischemia is caused by compromised blood flow to a lower limb and can affect up to 11% of patients undergoing complex cardiac surgery procedures.2 Consequences can include higher mortality, higher morbidity and longer hospital stays.3 The first procedure in Europe using a Bi-Flow cannula was performed by Patrick Perier M.D., FACS, at the Cardiovascular Center of Bad Neustadt, Germany. “I truly bel